CME/CE

AI Analysis of SD-OCT Shows Complement C3 Inhibition Preserves Photoreceptors in Geographic Atrophy

There are currently no FDA-approved treatments for geographic atrophy (GA), but it is a condition for which there are many potentially practice-changing developments on the horizon. A New Drug Application for intravitreal pegcetacoplan, a complement C3 inhibitor, has been submitted to the FDA, and a Prescription Drug User Fee Act target action date is set for February 2023. Recently, advanced imaging applying artificial intelligence (AI) to spectral domain-optical coherence tomography provided additional evidence supporting the use of intravitreal pegcetacoplan as a treatment for GA and demonstrated that AI can be an invaluable tool for monitoring GA disease activity and treatment response. This activity will review these new developments for clinicians treating patients with GA.

Experts Publish First Guidance on Use of Teprotumumab for Thyroid Eye Disease

Teprotumumab, a disease-modifying therapy, is currently the only drug approved by the FDA specifically for thyroid eye disease (TED). Despite being available since 2020, there are no guidelines to optimize its use in clinical practice. To address this gap, an expert panel came to a consensus on teprotumumab treatment recommendations, including when to initiate treatment, pretreatment considerations, monitoring throughout treatment, and strategies for mitigating and managing treatment-related adverse effects.